The stock will move on merger execution, not quarterly results. Monitor for regulatory and stockholder approvals for the Eos merger; failure to close would likely lead to cash depletion and delisting risk. The $1M preferred placement provides a short cash runway.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $1.25entry
- T+1 · 6mo ago +0.80%α +0.86% · $1.26
- T+5 · 6mo ago +7.20%α +6.24% · $1.34
- T+20 · 5mo ago +12.80%α +10.68% · $1.41
- T+60 · 3mo ago +28.00%α +23.48% · $1.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood at $3.3M with a going-concern qualification. The company is pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, having raised $1M in a private placement. This is a minimal-event filing for a pre-revenue entity reliant on merger completion.
Key Financial Metrics
Key Facts
- Net loss of $1.2M for Q1 2026 vs $1.8M in Q1 2025, improvement of 35%
- Cash and equivalents of $3.3M as of March 31, 2026, down from $4.1M at year-end 2025
- Financial statements prepared on a going-concern basis
- All clinical development on hold while seeking to license or monetize assets
- Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026
- Raised $1M gross proceeds from private placement of Series B Convertible Preferred Stock
Financial Impact
Net loss improved to $1.2M from $1.8M; no revenue. Cash burn of ~$0.8M during the quarter.
Risk Factors
- Merger with Eos may not close, leaving the company without a viable path forward
- Cash of $3.3M is insufficient for long-term operations without additional funding or deal completion
- Ongoing going-concern qualification increases bankruptcy risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023367 |
| Document: form8-k.htm | 0001493152-26-023367 |
| Document: 0001493152-26-023367-index-headers.html | 0001493152-26-023367 |
| Document: 0001493152-26-023367-index.html | 0001493152-26-023367 |
| Document: 0001493152-26-023367.txt | 0001493152-26-023367 |
| 8-K Data (Synthetic) | 0001493152-26-023367 |
Track record
21 reports on PULM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
- Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
- Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
- Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
- Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
- Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
- Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers